Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾ÏÁ¾¿¡¼­ E-Cadherin¼¼Æ÷ºÎÂøºÐÀÚÀÇ ¹ßÇö°ú ¾ÏÁ¾ÀÇ Á¶Á÷ÇÐÀû ºÐÈ­µµ ¹× È£¸£¸ó ¼ö¿ëü¿ÍÀÇ »ó°ü°ü°è¿¡ ´ëÇÑ ¿¬±¸ E-Cadherin Expression in Breast Carcinoma: Correlation with Tumor Grade and Hormone Receptor

´ëÇѺ´¸®ÇÐȸÁö 1997³â 31±Ç 11È£ p.1172 ~ 1179
¹ÚÂù±Ý, °­ÇàÀÚ, ¹ÚÂùÇÊ,
¼Ò¼Ó »ó¼¼Á¤º¸
¹ÚÂù±Ý (  ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

°­ÇàÀÚ (  ) 
»ï¼ºÁ¦ÀϺ´¿ø º´¸®Çб³½Ç
¹ÚÂùÇÊ (  ) 
»ï¼ºÁ¦ÀϺ´¿ø º´¸®Çб³½Ç

Abstract

E-cadherin (E-CD), a Ca2+ -dependent adhesion molecule, plays a major
role in the maintenance of intercellular junctions in normal epithelial cells in mosts
organs. Recently, a correlation has been observed between a loss of E-CD and increased
invasiveness of neoplastic cells. In this study, E-CD expression in the breast carcinoma
was investigated using monoclonal antibody, anti-E-CD by immunohistochemical method.
Expression of E-CD were evaluated in 57 breast carcinomas and correlated with their
tumor grade, lymph node involvement, and hormonal receptor status. Histological types
included in this study were 54 invasive ductal carcinomas (IDCs) of otherwise not
specified and 3 invasive lobular carcinomas. Cases of histologic grade ¥° IDC were 6,
grade ¥± 30, and grade ¥² 18. Of 54 IDCs 39 (72.2%) showed moderate to strong linear
staining at the cell borders regardless of their histologic grade, status of lymph node
metastasis, and status of hormone receptor. Staining intensity of E-CD was reduced in
54 cases(83%) of IDC when compared with that of normal or benign breast lesions
(P<0.01). All .seven cases of intraductal carcinoma, which .were included in 54 IDCs
showed one or two grade reduced expression of E-CD than that of infiltrative lesions.
Three invasive lobular carcinomas showed strong (1 case), moderate (1 case), and
negative reactivity (1 case). The data indicated that loss of E-CD expression is a c°Ü
cial event in the development of breast carcinoma.

Å°¿öµå

E-Cadherin; Breast carcinoma; Tumor grade; Hormone receptor;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS